Maze Therapeutics’ (MAZE) “Buy” Rating Reiterated at BTIG Research

Maze Therapeutics (NASDAQ:MAZE)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a note issued to investors on Wednesday,Benzinga reports. They presently have a $46.00 price objective on the stock. BTIG Research’s price target points to a potential upside of 37.99% from the stock’s current price.

A number of other brokerages have also weighed in on MAZE. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Wells Fargo & Company began coverage on Maze Therapeutics in a research report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. HC Wainwright upped their target price on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Finally, Guggenheim boosted their price target on Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $64.11.

Maze Therapeutics Price Performance

Shares of MAZE stock traded down $15.67 on Wednesday, hitting $33.34. 6,300,300 shares of the company’s stock were exchanged, compared to its average volume of 609,938. The company has a 50 day moving average of $46.16 and a 200 day moving average of $37.60. The stock has a market cap of $1.60 billion, a P/E ratio of -1.60 and a beta of 4.47. Maze Therapeutics has a 12 month low of $6.71 and a 12 month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter.

Insider Buying and Selling at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $44.27, for a total value of $332,025.00. Following the completion of the sale, the insider owned 10,503 shares of the company’s stock, valued at approximately $464,967.81. This represents a 41.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $49.10, for a total value of $736,500.00. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 245,000 shares of company stock worth $10,504,792.

Hedge Funds Weigh In On Maze Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of MAZE. Ensign Peak Advisors Inc bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at about $227,000. Frazier Life Sciences Management L.P. increased its holdings in Maze Therapeutics by 10.6% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after purchasing an additional 438,274 shares in the last quarter. Washington University acquired a new position in Maze Therapeutics in the third quarter valued at approximately $5,463,000. ArrowMark Colorado Holdings LLC bought a new position in shares of Maze Therapeutics during the 3rd quarter worth approximately $14,135,000. Finally, Virtus Investment Advisers LLC bought a new position in shares of Maze Therapeutics during the 2nd quarter worth approximately $85,000.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Positive Phase 2 HORIZON topline results for MZE829: week‑12 data showed a 35.6% mean reduction in uACR in broad APOL1‑mediated kidney disease (AMKD) patients, 50% achieved >30% reduction, FSGS subgroup saw 61.8% mean reduction, and non‑diabetic AMKD patients had a 48.6% mean reduction. Company plans to advance MZE829 into a pivotal program — this is the core bullish catalyst that drove earlier large intraday moves. Phase 2 HORIZON Topline Data
• Positive Sentiment: Analyst upgrade and large price‑target increase: HC Wainwright raised its target from $60 to $110 and reiterated a Buy rating, implying substantial upside versus the recent share price — reinforcing investor conviction after the trial readout. HC Wainwright Price Target Raise
• Positive Sentiment: Board strengthening and corporate updates: Maze added Neil Kumar (BridgeBio founder/CEO) to the board and reported a strong balance sheet (~$360M cash & marketable securities) with runway into 2028 — supports funding for pivotal development programs. Board Appointment Q4 & FY2025 Results
• Neutral Sentiment: Media coverage and market reaction: Multiple outlets ran positive headlines (Investing.com, Business Insider, Benzinga), which amplified trading volume and short‑term volatility as investors digested the details. Investing.com Coverage Business Insider Coverage
• Negative Sentiment: Quarterly results showed a GAAP loss (EPS of -$0.65) — typical for clinical‑stage biotech but a reminder of ongoing R&D spend; some investors may use the loss and the sharp rally as reasons to take profits, contributing to downward pressure. Earnings Release

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.